| Investor | Rosalind Advisors, Inc. |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Rosalind Advisors, Inc. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | 13G/A | FENC / Fennec Pharmaceuticals Inc. | 2,746,840 | 3,041,533 | ||||
| 2026-05-12 | 13G/A | TLPH / Talphera, Inc. | 13,150,954 | 12,925,597 | ||||
| 2026-05-12 | 13G/A | PYPD / PolyPid Ltd. | 5,483,443 | 5,384,813 | ||||
| 2026-02-11 | 13G/A | US49721T1016 / KIORA PHARMACEUTICALS INC | 464,676 | 464,676 | ||||
| 2026-02-11 | 13G/A | FENC / Fennec Pharmaceuticals Inc. | 2,076,840 | 2,746,840 | ||||
| 2026-02-11 | 13G/A | 912,319 | ||||||
| 2026-02-11 | 13G/A | PYPD / PolyPid Ltd. | 5,705,555 | 5,483,443 | ||||
| 2026-02-11 | 13G/A | NSPR / InspireMD, Inc. | 10,987,104 | 10,987,104 | ||||
| 2026-02-11 | 13G/A | BFRI / Biofrontera Inc. | 16,777,017 | 16,188,781 | ||||
| 2026-02-11 | 13G/A | TLPH / Talphera, Inc. | 13,957,438 | 13,150,954 | ||||
| 2026-02-11 | 13G/A | MYO / Myomo, Inc. | 7,554,046 | 7,603,030 | ||||
| 2026-02-10 | 13G/A | CLRB / Cellectar Biosciences, Inc. | 7,472,745 | 247,715 | ||||
| 2026-02-10 | 13D/A | DCTH / Delcath Systems, Inc. | 6,674,993 | 6,719,993 | ||||
| 2025-11-13 | 13G | FENC / Fennec Pharmaceuticals Inc. | 2,076,840 | |||||
| 2025-11-13 | 13G/A | TLPH / Talphera, Inc. | 7,642,515 | 13,957,438 | ||||
| 2025-11-12 | 13G/A | BFRI / Biofrontera Inc. | 14,432,072 | 16,777,017 | ||||
| 2025-11-12 | 13G/A | PYPD / PolyPid Ltd. | 5,762,349 | 5,705,555 | ||||
| 2025-11-12 | 13G/A | 912,319 | ||||||
| 2025-11-12 | 13G/A | MYO / Myomo, Inc. | 7,359,046 | 7,554,046 | ||||
| 2025-08-13 | 13G/A | PYPD / PolyPid Ltd. | 4,081,088 | 5,762,349 | ||||
| 2025-08-13 | 13G/A | US49721T1016 / KIORA PHARMACEUTICALS INC | 715,231 | 464,676 | ||||
| 2025-08-12 | 13G/A | 570,326 | ||||||
| 2025-08-11 | 13G/A | OPTN / OptiNose, Inc. | 343,781 | 0 | ||||
| 2025-08-11 | 13G/A | MYO / Myomo, Inc. | 7,279,046 | 7,359,046 | ||||
| 2025-08-11 | 13G/A | NSPR / InspireMD, Inc. | 9,713,171 | 10,987,104 | ||||
| 2025-08-11 | 13G/A | BFRI / Biofrontera Inc. | 9,886,969 | 14,432,072 | ||||
| 2025-08-11 | 13G/A | NSPR / InspireMD, Inc. | 9,713,171 | 10,987,104 | ||||
| 2025-08-11 | 13G/A | NSPR / InspireMD, Inc. | 9,713,171 | 10,987,104 | ||||
| 2025-05-13 | 13G/A | BFRI / Biofrontera Inc. | 9,962,649 | 9,886,969 | ||||
| 2025-05-12 | 13G/A | 670,158 | ||||||
| 2025-05-12 | 13G/A | OPTN / OptiNose, Inc. | 964,587 | 343,781 | ||||
| 2025-05-12 | 13G/A | NSPR / InspireMD, Inc. | 9,933,964 | 9,713,171 | ||||
| 2025-05-12 | 13G/A | MYO / Myomo, Inc. | 7,574,330 | 7,279,046 | ||||
| 2025-05-12 | 13D/A | DCTH / Delcath Systems, Inc. | 6,659,993 | 6,674,993 | ||||
| 2025-04-11 | 13G | TLPH / Talphera, Inc. | 7,642,515 | |||||
| 2025-02-14 | 13G/A | PYPD / PolyPid Ltd. | 4,081,088 | |||||
| 2025-02-13 | 13G/A | TRVI / Trevi Therapeutics, Inc. | 750,000 | 1,062,500 | ||||
| 2025-02-13 | 13G/A | SPRBD / Spruce Biosciences, Inc. | 0 | 0 | ||||
| 2025-02-12 | 13G/A | BFRI / Biofrontera Inc. | 426,002 | 9,962,649 | ||||
| 2025-02-11 | 13G/A | 628,050 | 791,315 | |||||
| 2025-02-10 | 13G/A | PYPD / PolyPid Ltd. | 679,168 | 4,085,588 | ||||
| 2025-02-10 | 13G/A | US49721T1016 / KIORA PHARMACEUTICALS INC | 2,300,000 | 715,231 | ||||
| 2025-02-07 | 13G/A | OPTN / OptiNose, Inc. | 964,587 | |||||
| 2025-02-07 | 13G/A | NSPR / InspireMD, Inc. | 2,514,046 | 9,933,964 | ||||
| 2025-02-04 | 13G/A | MYO / Myomo, Inc. | 3,021,391 | 7,574,330 | ||||
| 2025-02-03 | 13G/A | CLRB / Cellectar Biosciences, Inc. | 3,671,550 | 7,472,745 | ||||
| 2025-01-27 | 13D/A | DCTH / Delcath Systems, Inc. | 2,763,468 | 6,659,993 | ||||
| 2024-12-02 | 13D | NRXS / NeurAxis, Inc. | 2,100,840 | |||||
| 2024-12-02 | 13G | NRXS / NeurAxis, Inc. | 2,100,840 | |||||
| 2024-11-14 | 13D/A | DCTH / Delcath Systems, Inc. | 2,763,468 | 2,763,468 | ||||
| 2024-11-14 | 13D/A | DCTH / Delcath Systems, Inc. | 2,763,468 | 2,763,468 | ||||
| 2024-11-06 | 13G/A | BFRI / Biofrontera Inc. | 495,490 | 426,002 | ||||
| 2024-10-28 | 13G/A | NSPR / InspireMD, Inc. | 2,513,641 | 2,514,046 | ||||
| 2024-10-23 | 13G/A | BFRI / Biofrontera Inc. | 504,261 | 495,490 | ||||
| 2024-10-23 | 13G/A | PYPD / PolyPid Ltd. | 679,688 | 679,168 | ||||
| 2024-10-23 | 13G/A | MDWD / MediWound Ltd. | 513,490 | 628,050 | ||||
| 2024-10-23 | 13G/A | TRVI / Trevi Therapeutics, Inc. | 1,391,577 | 750,000 | ||||
| 2024-10-23 | 13G/A | SPRBD / Spruce Biosciences, Inc. | 1,508,419 | 0 | ||||
| 2024-10-18 | 13G/A | OPTN / OptiNose, Inc. | 7,547,148 | 8,287,503 | ||||
| 2024-10-18 | 13G/A | MYO / Myomo, Inc. | 2,664,999 | 3,021,391 | ||||
| 2024-08-14 | 13G/A | PYPD / PolyPid Ltd. | 415,800 | 679,688 | ||||
| 2024-08-14 | 13G/A | CLRB / Cellectar Biosciences, Inc. | 2,709,516 | 3,671,550 | ||||
| 2024-07-11 | 13G/A | MYO / Myomo, Inc. | 2,447,740 | 2,664,999 | ||||
| 2024-07-11 | 13G/A | MYO / Myomo, Inc. | 2,447,740 | 2,664,999 | ||||
| 2024-07-11 | 13G/A | TRVI / Trevi Therapeutics, Inc. | 926,016 | 1,391,577 | ||||
| 2024-07-11 | 13G/A | NSPR / InspireMD, Inc. | 2,492,765 | 2,513,641 | ||||
| 2024-07-11 | 13G/A | MDWD / MediWound Ltd. | 485,990 | 513,490 | ||||
| 2024-07-11 | 13G/A | CLRB / Cellectar Biosciences, Inc. | 3,305,936 | 2,709,516 | ||||
| 2024-05-29 | 13G | US49721T1016 / KIORA PHARMACEUTICALS INC | 2,300,000 | |||||
| 2024-05-29 | 13G/A | OPTN / OptiNose, Inc. | 4,541,489 | 7,547,148 | ||||
| 2024-05-29 | 13G | US49721T1016 / KIORA PHARMACEUTICALS INC | 2,300,000 | |||||
| 2024-05-29 | 13G/A | BFRI / Biofrontera Inc. | 504,261 | 504,261 | ||||
| 2024-05-17 | 13G/A | NSPR / InspireMD, Inc. | 1,371,126 | 2,492,765 | ||||
| 2024-05-17 | 13D/A | DCTH / Delcath Systems, Inc. | 1,151,907 | 2,763,468 | ||||
| 2024-04-25 | 13G/A | CLRB / Cellectar Biosciences, Inc. | 1,488,400 | 3,305,936 | ||||
| 2024-04-25 | 13G/A | TRVI / Trevi Therapeutics, Inc. | 2,499,993 | 926,016 | ||||
| 2024-04-25 | 13G/A | NSPR / InspireMD, Inc. | 989,940 | 1,371,126 | ||||
| 2024-04-25 | 13G/A | MDWD / MediWound Ltd. | 479,990 | 485,990 | ||||
| 2024-04-25 | 13G/A | MYO / Myomo, Inc. | 2,433,740 | 2,447,740 | ||||
| 2024-04-25 | 13G/A | OPTN / OptiNose, Inc. | 4,885,580 | 4,541,489 | ||||
| 2024-04-25 | 13G/A | SPRB / Spruce Biosciences, Inc. | 2,322,000 | 1,508,419 | ||||
| 2024-03-25 | 13D/A | DCTH / Delcath Systems, Inc. | 1,098,143 | 1,151,907 | ||||
| 2024-03-20 | 13G | BFRI / Biofrontera Inc. | 504,261 | 504,261 | ||||
| 2024-03-20 | 13G | BFRI / Biofrontera Inc. | 504,261 | |||||
| 2024-03-01 | 13G | PYPD / PolyPid Ltd. | 415,800 | |||||
| 2024-02-22 | 13G/A | OPTN / OptiNose, Inc. | 6,435,000 | 4,885,580 | ||||
| 2024-02-20 | 13G/A | GTHP / Guided Therapeutics, Inc. | 2,338,740 | 0 | ||||
| 2024-02-20 | 13G/A | SIENQ / Sientra, Inc. | 509,274 | 0 | ||||
| 2024-02-14 | 13G/A | MYO / Myomo, Inc. | 2,661,418 | 2,433,740 | ||||
| 2024-02-14 | 13G/A | MYO / Myomo, Inc. | 2,661,418 | 2,433,740 | ||||
| 2024-02-14 | 13G/A | NSPR / InspireMD, Inc. | 989,940 | |||||
| 2024-02-14 | 13G/A | MDWD / MediWound Ltd. | 444,326 | 479,990 | ||||
| 2024-02-14 | 13G/A | MDWD / MediWound Ltd. | 444,326 | 479,990 | ||||
| 2024-02-14 | 13G/A | CLRB / Cellectar Biosciences, Inc. | 986,293 | 1,488,400 | ||||
| 2024-01-30 | 13G | SPRB / Spruce Biosciences, Inc. | 2,322,000 | |||||
| 2023-11-28 | 13D/A | DCTH / Delcath Systems, Inc. | 701,500 | 1,098,143 | ||||
| 2023-08-28 | 13G/A | MYO / Myomo, Inc. | 553,290 | 2,661,418 | ||||
| 2023-07-28 | 13G | OPTN / OptiNose, Inc. | 6,435,000 | 6,435,000 | ||||
| 2023-06-08 | 13G | NSPR / InspireMD, Inc. | 1,860,405 | |||||
| 2023-02-15 | 13G | SIENQ / Sientra, Inc. | 509,274 | |||||
| 2023-02-15 | 13G | TRVI / Trevi Therapeutics, Inc. | 2,185,664 | 2,499,993 | ||||
| 2023-02-14 | 13G/A | CLRB / Cellectar Biosciences, Inc. | 605,228 | 986,293 | ||||
| 2022-12-21 | 13G | MDWD / MediWound Ltd. | 444,326 | |||||
| 2022-12-21 | 13D/A | DCTH / Delcath Systems, Inc. | 701,500 | 701,500 | ||||
| 2022-11-03 | 13G/A | CLRB / Cellectar Biosciences, Inc. | 6,052,282 | 605,228 | ||||
| 2022-07-21 | 13D/A | DCTH / Delcath Systems, Inc. | 423,500 | 701,500 | ||||
| 2022-07-06 | 13G | GTHP / Guided Therapeutics, Inc. | 2,338,740 | |||||
| 2022-03-09 | 13G | TRVI / Trevi Therapeutics, Inc. | 2,185,664 | |||||
| 2022-03-09 | 13D/A | DCTH / Delcath Systems, Inc. | 406,500 | 423,500 | ||||
| 2022-02-14 | 13D/A | DCTH / Delcath Systems, Inc. | 406,500 | 406,500 | ||||
| 2022-02-14 | 13G/A | PHAS / PhaseBio Pharmaceuticals Inc | 2,607,857 | 707,467 | ||||
| 2022-02-14 | 13G/A | PLXP / PLx Pharma Inc. | 970,425 | 0 | ||||
| 2022-02-11 | 13G | GRTX / Galera Therapeutics, Inc. | 1,543,783 | |||||
| 2022-01-21 | 13G/A | CLRB / Cellectar Biosciences, Inc. | 3,207,160 | 6,052,282 | ||||
| 2022-01-20 | 13G/A | UNCY / Unicycive Therapeutics, Inc. | 812,555 | 969,484 | ||||
| 2022-01-20 | 13G/A | MYO / Myomo, Inc. | 365,900 | 553,290 | ||||
| 2022-01-07 | 13G | ATXS / Astria Therapeutics, Inc. | 653,438 | |||||
| 2021-09-23 | 13G | UNCY / Unicycive Therapeutics, Inc. | 812,555 | |||||
| 2021-07-08 | 13G | CLRB / Cellectar Biosciences, Inc. | 3,207,160 | |||||
| 2021-06-25 | 13D/A | DCTH / Delcath Systems, Inc. | 406,500 | 406,500 | ||||
| 2021-05-19 | 13G | PHAS / PhaseBio Pharmaceuticals Inc | 2,607,857 | |||||
| 2021-05-19 | 13G | MYO / Myomo, Inc. | 365,900 | |||||
| 2021-04-06 | 13D/A | DCTH / Delcath Systems, Inc. | 701,500 | 406,500 | ||||
| 2021-01-22 | 13G/A | PLXP / PLx Pharma Inc. | 970,425 | 970,425 | ||||
| 2021-01-22 | 13G/A | VTGN / Vistagen Therapeutics, Inc. | 4,000,000 | 5,377,113 | ||||
| 2020-12-18 | 13G | PLXP / PLx Pharma Inc. | 970,425 | |||||
| 2020-09-18 | 13G | VTGN / Vistagen Therapeutics, Inc. | 4,000,000 | |||||
| 2020-05-14 | 13D/A | DCTH / Delcath Systems, Inc. | 853,950 | 701,500 | ||||
| 2020-04-10 | 13D/A | DCTH / Delcath Systems, Inc. | 853,950 | 853,950 | ||||
| 2020-04-09 | 13D/A | DCTH / Delcath Systems, Inc. | 853,950 | 853,950 | ||||
| 2020-03-12 | 13D | DCTH / Delcath Systems, Inc. | 853,950 | 853,950 | ||||
| 2020-03-11 | 13D | DCTH / Delcath Systems, Inc. | 853,950 | 853,950 | ||||
| 2020-03-06 | 13G/A | DCTH / Delcath Systems, Inc. | 468,452 | 853,950 | ||||
| 2020-02-13 | 13G/A | DCTH / Delcath Systems, Inc. | 280,000,000 | 468,452 | ||||
| 2019-08-01 | 13G | DCTH / Delcath Systems, Inc. | 280,000,000 | |||||
| 2019-07-24 | 13G/A | US16706W1027 / Chiasma Inc | 2,003,478 | 936,651 | ||||
| 2019-02-15 | 13G/A | US16706W1027 / Chiasma Inc | 2,003,478 | 2,003,478 | ||||
| 2019-02-15 | 13G/A | H03579101 / Auris Medical Holding Ltd | 420,000 | 420,000 | ||||
| 2019-02-14 | 13G/A | TNXP / Tonix Pharmaceuticals Holding Corp. | 594,077 | 40,169 | ||||
| 2019-02-14 | 13G/A | 76028H209 / Repros Therapeutics, Inc. | 3,332,292 | 0 | ||||
| 2019-02-14 | 13G/A | US16706W1027 / Chiasma Inc | 1,459,100 | 2,003,478 | ||||
| 2019-02-14 | 13G/A | H03579101 / Auris Medical Holding Ltd | 2,050,489 | 420,000 | ||||
| 2018-11-23 | 13G | US16706W1027 / Chiasma Inc | 1,459,100 | 1,459,100 | ||||
| 2018-11-21 | 13G | US16706W1027 / Chiasma Inc | 1,459,100 | |||||
| 2018-08-10 | 13G | H03579101 / Auris Medical Holding Ltd | 2,050,489 | |||||
| 2018-05-15 | 13G/A | PPBT / Purple Biotech Ltd - Depositary Receipt (Common Stock) | 1,105,600 | 541,600 | ||||
| 2018-02-14 | 13G/A | TNXP / Tonix Pharmaceuticals Holding Corp. | 594,077 | 594,077 | ||||
| 2018-02-09 | 13G/A | PSDV / pSivida Corp. | 2,126,800 | 2,235,355 | ||||
| 2018-02-09 | 13G/A | ZSAN / Zosano Pharma Corp | 2,083,100 | 32,500 | ||||
| 2018-02-01 | 13G | PPBT / Purple Biotech Ltd - Depositary Receipt (Common Stock) | 1,105,600 | |||||
| 2018-01-02 | 13G/A | 76028H209 / Repros Therapeutics, Inc. | 2,105,626 | 3,332,292 | ||||
| 2017-07-24 | 13G | 76028H209 / Repros Therapeutics, Inc. | 2,105,626 | |||||
| 2017-04-07 | 13G/A | TNXP / Tonix Pharmaceuticals Holding Corp. | 2,220,055 | 594,077 | ||||
| 2017-04-07 | 13G | PSDV / pSivida Corp. | 2,126,800 | |||||
| 2017-03-29 | 13G/A | ZSAN / Zosano Pharma Corp | 2,083,100 | 2,083,100 | ||||
| 2017-03-28 | 13G/A | ZSAN / Zosano Pharma Corp | 2,023,777 | 2,083,100 | ||||
| 2016-11-30 | 13G | TNXP / Tonix Pharmaceuticals Holding Corp. | 2,220,055 | |||||
| 2016-11-16 | 13G | ZSAN / Zosano Pharma Corp | 2,023,777 | |||||
| 2016-02-16 | 13G/A | ALBO / Albireo Pharma Inc | 3,592,889 | 590,590 | ||||
| 2015-08-26 | 13G | ALBO / Albireo Pharma Inc | 2,883,313 | 3,592,889 | ||||
| 2015-04-23 | 13G/A | ALBO / Albireo Pharma Inc | 2,883,313 | |||||
| 2014-10-24 | 13G | ALBO / Albireo Pharma Inc | 1,265,492 |
